Tvardi's TTI-101 breast cancer trial posts results after early terminationSep 24Trial updateTTI-101Tvardi Therapeutics, Incorporated
AstraZeneca's SERENA-4 trial misses main goal for Etcamah in first-line breast cancerSep 14Clinical readoutAstraZenecacamizestrant
FDA approves AstraZeneca's Etcamah for HR-positive breast cancerSep 8Regulatory decisionAstraZenecacamizestrant
FDA drug application records confirm Etcamah approval details, dosage formSep 4Regulatory decisionAstraZenecacamizestrant
Novartis roundup: ITP real-world data completed; three trials registered; Utah study terminatedSep 4Weekly roundup, 6 itemsDDY391inclisiran
Novartis: TOUR006 Phase 2 results posted in CKD; eltrombopag pediatric PK study also reports outAug 12Weekly roundup, 5 itemseltrombopagNovartis
Olema completes OPERA-01 enrollment, pushes top-line data to Q1 2027Aug 10Quarterly updateOlema Pharmaceuticals, Inc.
AstraZeneca's Etcamah wins EU approval for 1st-line ER+ breast cancerJul 23Regulatory decisionAstraZenecacamizestrant
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
Novartis posts BioItaLEE and China ribociclib results; registers three new studiesJul 10Weekly roundup, 5 itemsalpelisibinclisiran
Sign inSign in